Solid Biosciences Inc. (SLDB)
| Market Cap | 986.47M +89.6% |
| Revenue (ttm) | n/a |
| Net Income | -207.10M |
| EPS | -1.87 |
| Shares Out | 107.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 759,399 |
| Open | 9.09 |
| Previous Close | 9.08 |
| Day's Range | 8.73 - 9.35 |
| 52-Week Range | 3.79 - 11.45 |
| Beta | 2.42 |
| Analysts | Strong Buy |
| Price Target | 17.64 (+91.74%) |
| Earnings Date | Aug 6, 2026 |
About SLDB
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treat... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for SLDB stock is "Strong Buy." The 12-month stock price target is $17.64, which is an increase of 91.74% from the latest price.
News
Solid Biosciences reports Q2 EPS (38c), consensus (47c)
Bo Cumbo, President and CEO of Solid Biosciences (SLDB), stated: “Our progress in the first half of 2026 positions us for continued momentum as we approach multiple key clinical and…
Solid Biosciences files automatic mixed securities shelf
17:01 EDT Solid Biosciences (SLDB) files automatic mixed securities shelf
Solid Biosciences Quarterly report: Q2 2026
Solid Biosciences has published its Q2 2026 quarterly earnings report on August 6, 2026.
Solid Biosciences Earnings release: Q2 2026
Solid Biosciences released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Solid Biosciences Transcript: AGM 2026
The meeting confirmed quorum, elected directors, ratified the auditor, and approved doubling authorized shares. All proposals passed, with final results to be filed in Form 8-K. No questions were raised by stockholders during the session.
Solid Biosciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The pipeline features advanced gene therapies for Duchenne and Friedreich's ataxia, with strong safety and efficacy signals in ongoing trials. Unique transgene and capsid designs drive superior tissue targeting and biomarker improvements, while regulatory and commercial milestones are expected in 2024–2025.
Solid Biosciences Transcript: Jefferies Global Healthcare Conference 2026
Key programs in Duchenne and Friedreich's ataxia are advancing, with robust biomarker and safety data supporting clinical benefit. FDA feedback has shaped trial design and data analysis, with pivotal discussions and potential accelerated approval expected later this year.
Solid Biosciences price target raised to $25 from $20 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Solid Biosciences (SLDB) to $25 from $20 and keeps a Buy rating on the shares. The firm views the company’s SGT-212 program…
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardia...
Solid Biosciences to Participate at Upcoming Investor Conferences
CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular...
Solid Biosciences price target lowered to $16 from $17 at Wedbush
Wedbush lowered the firm’s price target on Solid Biosciences (SLDB) to $16 from $17 and keeps an Outperform rating on the shares. Most important in the Q1 update from Solid…
Solid Biosciences price target raised to $18 from $17 at Piper Sandler
Piper Sandler analyst Biren Amin raised the firm’s price target on Solid Biosciences (SLDB) to $18 from $17 and keeps an Overweight rating on the shares. In Q1 financial results,…
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company's Pediatric Investigation Plan from the European Medicines Agenc...
Solid Biosciences Quarterly report: Q1 2026
Solid Biosciences has published its Q1 2026 quarterly earnings report on May 12, 2026.
Solid Biosciences Earnings release: Q1 2026
Solid Biosciences released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Solid Biosciences doses part participant in IMPACT DUCHENNE study
Solid Biosciences (SLDB) announced that the first participant has been dosed in IMPACT DUCHENNE, the company’s multi-country, placebo-controlled, randomized, double-blind, Phase 3 clinical trial inves...
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid's integrated, multi-trial development program designed to support registration and global re...
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
- Solid Biosciences delivers its largest scientific program at the 2026 ASGCT Annual Meeting with 5 oral presentations and 11 posters - CHARLESTOWN, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Solid Bi...
Solid Biosciences receives orphan drug designation for SGT-003 from EC
Solid Biosciences (SLDB) announced that the European Commission, acting upon the positive opinion from the European Medicines Agency Committee for Orphan Medicinal Products, has granted orphan drug de...
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
- Orphan drug designation from the European Commission underscores Solid's commitment to advance SGT-003 through a global development effort for individuals living with Duchenne muscular dystrophy - ...
Solid Biosciences Proxy statement: Proxy filing
Solid Biosciences filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Solid Biosciences Proxy statement: Proxy filing
Solid Biosciences filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Solid Biosciences Transcript: 25th Annual Needham Virtual Healthcare Conference
The presentation highlighted robust clinical and biomarker data for DMD and FA gene therapy programs, emphasizing unique capsid design, strong safety, and early functional improvements. Plans include expanding cardiac programs, licensing next-gen capsids, and a major FA data readout by year-end.
Solid Biosciences Proxy statement: Proxy filing
Solid Biosciences filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
Solid Biosciences price target raised to $12 from $11 at JPMorgan
JPMorgan raised the firm’s price target on Solid Biosciences (SLDB) to $12 from $11 and keeps an Overweight rating on the shares. The firm updated models in the small-cap biotech…